TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System

ABSTRACT Background - Terlipressin and noradrenaline are the best studied treatments for hepatorenal syndrome, and there is no evidence of superiority of one over the other regarding to efficacy. While the former drug is more costly, the latter requires admission into an intensive care unit. Obje...

Full description

Bibliographic Details
Main Authors: Ângelo Zambam de MATTOS, Angelo Alves de MATTOS, Rodrigo Antonini RIBEIRO
Format: Article
Language:English
Published: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
Series:Arquivos de Gastroenterologia
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000200123&lng=en&tlng=en
_version_ 1811226125606584320
author Ângelo Zambam de MATTOS
Angelo Alves de MATTOS
Rodrigo Antonini RIBEIRO
author_facet Ângelo Zambam de MATTOS
Angelo Alves de MATTOS
Rodrigo Antonini RIBEIRO
author_sort Ângelo Zambam de MATTOS
collection DOAJ
description ABSTRACT Background - Terlipressin and noradrenaline are the best studied treatments for hepatorenal syndrome, and there is no evidence of superiority of one over the other regarding to efficacy. While the former drug is more costly, the latter requires admission into an intensive care unit. Objective - The aim of this study was to perform an economic evaluation, comparing treatments for hepatorenal syndrome with terlipressin and noradrenaline. Methods - For the economic evaluation, a cost-minimization analysis was performed. Direct medical costs of the two treatment strategies were compared under the perspective of the Brazilian Public Health System as the third-party payer. A probabilistic sensitivity analysis was performed. Results - The costs of treatments with terlipressin or noradrenaline were 287.77 and 2,960.45 International Dollars (Int$) respectively. Treatment using terlipressin would save Int$2,672.68 for the Public Health System for each hospital admission related to hepatorenal syndrome. In the probabilistic sensitivity analysis, it was verified that the cost of the treatment with noradrenaline could vary between Int$2,326.53 and Int$3,644.16, while costs related to the treatment using terlipressin are not variable. Conclusion - The treatment strategy using terlipressin was more economical than that using noradrenaline under the perspective of the Brazilian Public Health System as the third-party payer.
first_indexed 2024-04-12T09:19:03Z
format Article
id doaj.art-255205e7c2444d9ebde512c151d1c8d2
institution Directory Open Access Journal
issn 1678-4219
language English
last_indexed 2024-04-12T09:19:03Z
publisher Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
record_format Article
series Arquivos de Gastroenterologia
spelling doaj.art-255205e7c2444d9ebde512c151d1c8d22022-12-22T03:38:43ZengInstituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)Arquivos de Gastroenterologia1678-421953212312610.1590/S0004-28032016000200014S0004-28032016000200123TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health SystemÂngelo Zambam de MATTOSAngelo Alves de MATTOSRodrigo Antonini RIBEIROABSTRACT Background - Terlipressin and noradrenaline are the best studied treatments for hepatorenal syndrome, and there is no evidence of superiority of one over the other regarding to efficacy. While the former drug is more costly, the latter requires admission into an intensive care unit. Objective - The aim of this study was to perform an economic evaluation, comparing treatments for hepatorenal syndrome with terlipressin and noradrenaline. Methods - For the economic evaluation, a cost-minimization analysis was performed. Direct medical costs of the two treatment strategies were compared under the perspective of the Brazilian Public Health System as the third-party payer. A probabilistic sensitivity analysis was performed. Results - The costs of treatments with terlipressin or noradrenaline were 287.77 and 2,960.45 International Dollars (Int$) respectively. Treatment using terlipressin would save Int$2,672.68 for the Public Health System for each hospital admission related to hepatorenal syndrome. In the probabilistic sensitivity analysis, it was verified that the cost of the treatment with noradrenaline could vary between Int$2,326.53 and Int$3,644.16, while costs related to the treatment using terlipressin are not variable. Conclusion - The treatment strategy using terlipressin was more economical than that using noradrenaline under the perspective of the Brazilian Public Health System as the third-party payer.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000200123&lng=en&tlng=enSíndrome hepatorrenalVasoconstritoresAvaliação em saúde.
spellingShingle Ângelo Zambam de MATTOS
Angelo Alves de MATTOS
Rodrigo Antonini RIBEIRO
TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System
Arquivos de Gastroenterologia
Síndrome hepatorrenal
Vasoconstritores
Avaliação em saúde.
title TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System
title_full TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System
title_fullStr TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System
title_full_unstemmed TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System
title_short TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System
title_sort terlipressin versus noradrenaline for hepatorenal syndrome economic evaluation under the perspective of the brazilian public health system
topic Síndrome hepatorrenal
Vasoconstritores
Avaliação em saúde.
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000200123&lng=en&tlng=en
work_keys_str_mv AT angelozambamdemattos terlipressinversusnoradrenalineforhepatorenalsyndromeeconomicevaluationundertheperspectiveofthebrazilianpublichealthsystem
AT angeloalvesdemattos terlipressinversusnoradrenalineforhepatorenalsyndromeeconomicevaluationundertheperspectiveofthebrazilianpublichealthsystem
AT rodrigoantoniniribeiro terlipressinversusnoradrenalineforhepatorenalsyndromeeconomicevaluationundertheperspectiveofthebrazilianpublichealthsystem